A newly published research study in Experimental Neurology brought the focus back to the use of Decorin for chronic spinal cord injury. I’ve watched the development of various research studies surrounding the use of Decorin (an anti-scarring protein) over the past several years. In this latest study, Dr. Giles Plant of Stanford showed decorin infusion did improve tissue sparing, reduced spinal tissue cavitation and increased transplanted cell survivability as compared to controls. But disappointing were the results that showed Decorin did not increase axonal outgrowth from that achieved by hMPCs. There was no measurable improvement by recombinant decorin treatment. Not all research projects stand the test of time, but it’s important for the neuro researchers to dig deeper and work harder at verifying potential therapies that may hold promise for curative therapies for chronic paralysis. So now we are hearing the rest of the story from the scientist that spent three years studying this potential therapy for chronic’s (a promise previously made by another researcher back in 2005).
The abstract can be viewed HERE.
“Human bone marrow stromal cells (hBMSC) in combination with Decorin for repair of the injured spinal cord.”
Chief Investigators: Dr. Paul Simmons, Professor Silviu Itescu (UM), Dr. Giles Plant (UWA), Dr. Stuart Hodgetts (UWA)
Lead Organisations: Victoria Neuroscience Initiative(VNI)
StepAhead Australia Ltd
Collaborating Organisations: University of Western Australia; University of Melbourne (St. Vincent’s Hospital) Browns Foundation, Institute of Molecular Medicine, University of Texas Health Science Center. Houston
Project Commencement Date: August, 2007
Project Completion Date: November, 2010
Total Value of Project $936,000 over 3 years